PDCD1 and metastatic melanoma: In a phase Ib/II study cohort of 21 patients with metastatic melanoma who received ≤2 previous systemic therapies (62% were treatment-naïve), combined lenvatinib and pembrolizumab showed an ORR of 48%, 12.5-month median DOR, and 5.5-month median PFS.15 The phase II LEAP-004 study showed, in a cohort of 103 patients previously treated with anti-PD-1 with or without anti-CTLA-4, that the ORR was 21%, with a median DOR of 8.3 months.